NEURODEGENERATIVE DISEASES

This study tests whether donanemab can slow memory and thinking decline in people with early Alzheimer's disease. About 1,500 participants with mild symptoms and brain amyloid plaques will receive the drug or a placebo for up to 93 weeks. The main goal is to see if donanemab help…

This study tests whether changing the dose schedule of donanemab can lower the risk of a brain swelling side effect called ARIA-E while still clearing amyloid plaques. About 1,175 adults with early symptomatic Alzheimer's will receive different dosing regimens over 91 weeks. The …

This study aims to create detailed brain charts for the Chinese population by collecting MRI scans from over 10,000 healthy people of different ages. These charts will show what a normal brain looks like at each age, helping doctors detect diseases like multiple sclerosis, Alzhei…

This study is testing a new, comfortable headset that reads brain signals to help people with ALS type on a virtual keyboard. The goal is to see if the headset is easy to set up and use in daily life. Five people with ALS will try the device, and researchers will measure setup ti…

This study involves 100 people with Alzheimer's or similar conditions. Researchers are creating a simpler way to check if someone can understand and agree to medical decisions. They will also look at brain scans and blood markers to see how thinking ability connects to brain heal…